Indication
For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.

Medicine details

Medicine name:
ribociclib (Kisqali)
SMC ID:
SMC2198
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
Q4 2019
SMC meeting date:
Q4 2019
Patient group submission deadline:
05 August 2019